BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...